Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
Reva launches bioresorbable stent trial. Meta-analysis shows tests intended simply to reassure patients rarely do. Sorin launches trial of the SonR cardiac resynchronization system.
You may also be interested in...
New Products In Brief
New cancer companion diagnostic approved. Biotronik’s Ilesto 7 ICD and CRT-D earns FDA approval. More new product announcements.
People In Brief
Edwards Lifesciences chief financial officer to retire. Trice Orthopedics raises $3 million, names president. More people briefs
Sorin Hopes Improving CRT Response Rate Will Lead To Growth In U.S. Market
The Italian company is set to launch the RESPOND CRT trial of its SonR cardiac resynchronization therapy, which Sorin expects will be an important differentiator that allows the company to compete more aggressively in the U.S. market.